• Policy
• Zolgensma shows 94% effect during post-evaluations
• by Lee, Tak-Sun Jan 6, 2025 05:56am

• Policy
• MFDS’s 2nd GIFT drug Nefecon applies for reimbursement
• by Lee, Tak-Sun Jan 6, 2025 05:56am

• Policy
• 'Pivlaz Inj' makes another attempt to be reimb in KOR
• by Lee, Tak-Sun Jan 3, 2025 06:27am

• Policy
• New Year's drug pricing policy highlights
• by Lee, Tak-Sun Jan 3, 2025 06:27am

• Policy
• Prices for Vyndamax, Ocrevus in negotiations with NHIS
• by Lee, Tak-Sun Jan 3, 2025 06:27am

• Policy
• Orphan drug 'Voxzogo' wins nod
• by Lee, Hye-Kyung Jan 2, 2025 06:11am

• Policy
• Changes made to the drug approval system in the new year
• by Lee, Hye-Kyung Jan 2, 2025 06:11am

• Policy
• ICER threshold for anticancer drugs set same as in 2024
• by Lee, Tak-Sun Jan 2, 2025 06:10am

• Policy
• Once-weekly insulin 'Awiqli' wins nod in KOR
• by Lee, Hye-Kyung Dec 31, 2024 05:56am

• Policy
• Approval of the 48hr Nurtec ODT for migraine imminent in KOR
• by Lee, Hye-Kyung Dec 31, 2024 05:55am